Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claire Harrison

Showing results (141-150 of 218) with videos related to

Pageof 22
Sort By:
Hemasphere|August 12, 2024
Development of a natural language processing pipeline for assessment of cardiovascular risk in myeloproliferative neoplasmsAndrea Duminuco, Joshua Au Yeung, Raj Vaghela, et al.
The New England Journal of Medicine|March 2, 2012
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosisClaire Harrison, Jean-Jacques Kiladjian, Haifa Kathrin Al-Ali, et al.
Blood|July 11, 2013
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus reportAyalew Tefferi, Francisco Cervantes, Ruben Mesa, et al.
The Lancet. Haematology|August 27, 2021
Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNetAlberto Alvarez-Larrán, Emanuela Sant'Antonio, Claire Harrison, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 15, 2023
Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical OutcomesJohn Mascarenhas, Claire Harrison, Tammy A Schuler, et al.
British Journal of Haematology|November 26, 2009
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus processGiovanni Barosi, Gunnar Birgegard, Guido Finazzi, et al.
Molecular Biology and Evolution|November 3, 2025
Stable Hypermutators Revealed by the Genomic Landscape of Genes Involved in Genome Stability Among Yeast SpeciesCarla Gonçalves, Jacob L Steenwyk, David C Rinker, et al.
Biorxiv : the Preprint Server for Biology|April 1, 2025
Stable hypermutators revealed by the genomic landscape of DNA repair genes among yeast speciesCarla Gonçalves, Jacob L Steenwyk, David C Rinker, et al.
Hemasphere|August 8, 2022
A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in MyelofibrosisClaire Harrison, Florian H Heidel, Alessandro M Vannucchi, et al.
American Journal of Hematology|June 1, 2019
Facing erythrocytosis: Results of an international physician surveyElisa Rumi, Mary F McMullin, Claire Harrison, et al.
Pageof 22

Showing results (141-150 of 218) with videos related to

Sort By:
Pageof 22
Hemasphere|August 12, 2024
Development of a natural language processing pipeline for assessment of cardiovascular risk in myeloproliferative neoplasmsAndrea Duminuco, Joshua Au Yeung, Raj Vaghela, et al.
The New England Journal of Medicine|March 2, 2012
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosisClaire Harrison, Jean-Jacques Kiladjian, Haifa Kathrin Al-Ali, et al.
Blood|July 11, 2013
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus reportAyalew Tefferi, Francisco Cervantes, Ruben Mesa, et al.
The Lancet. Haematology|August 27, 2021
Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNetAlberto Alvarez-Larrán, Emanuela Sant'Antonio, Claire Harrison, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 15, 2023
Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical OutcomesJohn Mascarenhas, Claire Harrison, Tammy A Schuler, et al.
British Journal of Haematology|November 26, 2009
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus processGiovanni Barosi, Gunnar Birgegard, Guido Finazzi, et al.
Molecular Biology and Evolution|November 3, 2025
Stable Hypermutators Revealed by the Genomic Landscape of Genes Involved in Genome Stability Among Yeast SpeciesCarla Gonçalves, Jacob L Steenwyk, David C Rinker, et al.
Biorxiv : the Preprint Server for Biology|April 1, 2025
Stable hypermutators revealed by the genomic landscape of DNA repair genes among yeast speciesCarla Gonçalves, Jacob L Steenwyk, David C Rinker, et al.
Hemasphere|August 8, 2022
A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in MyelofibrosisClaire Harrison, Florian H Heidel, Alessandro M Vannucchi, et al.
American Journal of Hematology|June 1, 2019
Facing erythrocytosis: Results of an international physician surveyElisa Rumi, Mary F McMullin, Claire Harrison, et al.
Pageof 22